Denteric was established to develop and commercialise a Porphyromonas gingivalis (Pg) vaccine program originating from the University of Melbourne in collaboration with CSL. The company is advancing a therapeutic vaccine intended to treat moderate to severe periodontitis, a debilitating gum disease that affects roughly one in three adults globally and is linked to diabetes, heart disease, rheumatoid arthritis, dementia and certain cancers. There are currently no cures for periodontitis and existing treatments are described as archaic and painful. Denteric has received a $14 million Series A to progress the Pg vaccine research program. The funds will support work toward commencing the company’s first human clinical trial, planned in the next two to three years. The program and company are closely tied to the University of Melbourne’s Centre for Oral Health Research and CSL, reflecting continued public–private collaboration within the Melbourne biomedical precinct.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2022